AstraZeneca reports positive Faslodex data

AP News
|
Posted: Dec 10, 2009 5:54 PM

AstraZeneca said Thursday a high dose of its drug Faslodex reduced the risk of breast cancer progressing by 20 percent in patients during a late-stage study.

The study compared a 500-milligram dose versus a currently approved 250-milligram dose in postmenopausal women with advanced breast cancer.

The higher dose pushed back to 6.5 months from 5.5 months the amount of time it took for breast cancer to progress in patients.

American Depository Shares of London-based AstraZeneca closed unchanged at $45.35.